Starpharma signs Priostar Agrochemical Partnership with Gowan
Starpharma Holdings Ltd (ASX:SPL; OTCQX:SPHRY) and Gowan Company LLC today announced a new partnership using Starpharma’s Priostar® dendrimer technology in crop protection formulations.
Under the agreement, Starpharma’s Priostar® dendrimers will be evaluated as potential enhancements for certain Gowan products intended for high value markets.
Dendrimer-Oxaliplatin shows better anti-cancer efficacy and less toxicity
Melbourne, Australia: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it had achieved improved tumour-inhibiting efficacy and reduced overall toxicity using a dendrimer enhanced version of the blockbuster cancer drug, oxaliplatin (ELOXATIN®).
These positive results were demonstrated in a pre-clinical study, which examined dendrimer-enhanced nanoparticle versions of oxaliplatin compared with ELOXATIN® (oxaliplatin) in a colon cancer model (xenograft).
Eureka Report: Uncapped biotechs step up
|
Small caps reporter Brendon Lau, reported on Starpharma’s strong share price after the company announced improved efficacy and safety profile in its dendrimer-enhanced version of widely-used cancer drug oxaliplatin.
|
The Australian: Starpharma to develop improved cancer drug
|
The Australian online reported on Starpharma’s pre-clinical study of the effects of its dendrimer-enhanced oxaliplatin on colon cancer.
|
Herald Sun: Starpharma may be on to a good thing
Herald Sun business journalist John Beveridge reported on the versatility of Starpharma’s dendrimer technology.
"There is no secret why Starpharma is going after docetaxel given its sales of $US2.14 billion in 2009, but there is a long list of other potential drugs that could benefit from improved delivery mechanisms. The other thing I like about Starpharma is that it has lots of irons in the fire. Its phase-three Vivagel trials for relieving symptoms of bacterial vaginosis have potential to recover ground lost when trials as a cure for that disease marginally failed to reach their endpoint. Plus the potential for removing solvents and greatly improving the efficacy of a broad range of agricultural chemicals is a much-underestimated source of future profits for Starpharma."
Starpharma annual report and full year financial results
Starpharma today released its annual report and financial results for the year ended 30 June 2013.
Financial Results
- Net cash burn for the year $9.0M
- Cash position at end of the year $33.8M
- Reported loss $5.2M
Starpharma presentation at Canaccord Genuity Annual Growth Conference
Starpharma has announced that Chief Executive Officer Dr Jackie Fairley will present at the Canaccord Genuity 33rd Annual Growth Conference in Boston on August 14. The event brings together around 200 companies from diversified industry sectors, and selected from around the world based on their high growth potential.
Appendix 4C - Quarterly Cashflow Report
Starpharma today released its Appendix 4C - Quarterly Cashflow Report for the period ended 30 June 2013.
Eureka Report: Five bargains for under a buck
Eureka Report small caps reporter Brendon Lau interviewed Jackie Fairley citing Starpharma as a high-value biotech stock.
“I can’t remember a time when Starpharma had this many potential milestones over a relatively short period and even its chief executive, Jackie Fairley, describes the next six-months as the “most exciting” window in Starpharma’s history.”
Starpharma appoints Business Development executive
Starpharma today announced a new senior appointment to its experienced and successful business development team. Dr Tony Eglezos has been appointed to the position of VP of Business Development.
Tony has worked for more than 20 years in the pharmaceutical industry in Australia, the US and Europe for companies including CSL, Amgen, Abbott Labs and Abbott Australia.